Christopher Dunn

Bear, Stearns & Co., Inc. is a global investment banking, securities trading and brokerage firm located in New York City with additional offices in Dallas, Boston and San Francisco. The firm is a subsidiary Bear Sterns Cos., Inc. (NYSE: BSC). Their equity research team consists of senior analysts located throughout the world. In addition to domestic coverage, they have research teams focusing on Latin America, Asia and Europe. The analysts use a bottom-up approach to stock selection. The Bear Stearns fixed-income research department provides coverage of every sector of the fixed-income universe. The financial analytics and structured transactions group (F.A.S.T) provides investment research, fixed-income portfolio management and analytical systems, trading technology and general financial expertise. The group also provides a broad range of services to financial institutions including asset-liability management, balance sheet restructuring, receivables-based financing analysis, security and portfolio analysis, peer analysis, and historical and real-time market-based information.

True Gold Mining, Inc. explores and develops gold projects in West Africa. It holds interest in the Karma and Liguidi projects. True Gold Mining was founded on October 2, 1987 and is headquartered in Vancouver, Canada.

Pretium Resources, Inc. engages in the acquisition, exploration, development and operation of gold and precious metals resource properties. Its projects include Snowfield and Brucejack which are located in British Columbia. The company was founded by Robert Allan Quartermain in 2010 and is headquartered in Vancouver, Canada.

Part of Liberty Mutual Holding Co., Inc., Liberty Mutual Group Asset Management, Inc. is a company that offers various resources including the Liberty Mutual- Safeco Insurance Fund and Liberty Mutual- Employee Resource Groups. The company is based in Boston, MA. The company specializes in providing workers compensation insurance that covers lost wages and medical treatment resulting from an employee's work-related injury or illness.

Alzheon, Inc. engages in the provision of medical development. It specializes in treatment for brain health, memory, and aging. It offers ALZ-801, an oral small molecule inhibitor of amyloid formation and neurotoxicity with potential to be a therapy for a genetically defined population of patients with or at high risk for Alzheimer's disease and other neurodegenerative disorders. The company was founded by Martin Tolar in June 2013 and is headquartered in Framingham, MA.